[Tree] Algernon Pharmaceuticals' drug development and research focus

Version 0.07 (2024-12-16 15:56:51.609000)

updates: Algernon sells Ifenprodil, focuses on DMT for stroke treatment

  • ➔
Version 0.06 (2024-05-24 01:09:39.838000)

updates: Enterome's presentation at SNO 2023, Lucas's recovery from DIPG, Longeveron stock rally, Antengene's presentations at ASCO 2024

  • ➔
  • ➔
Version 0.05 (2024-04-15 14:22:33.585000)

updates: Add information about Longeveron stock rally on Alzheimer's presentation

  • ➔
Version 0.04 (2024-02-17 04:07:00.809000)

updates: Enterome to present updated data at SNO 2023, Belgian teen cured of DIPG

  • ➔
  • ➔
Version 0.03 (2023-11-13 11:30:47.493000)

updates: Revised and condensed story about Enterome's Phase 1/2 trial of EO2401 in recurrent glioblastoma

  • ➔
Version 0.02 (2023-10-27 15:35:25.854000)

updates: Combined two health-related stories into one

  • ➔
  • ➔
Version 0.01 (2023-10-24 14:10:35.368000)

updates: The narrative highlights the breakthrough in lung cancer treatment using AI-driven immune phenotyping.

  • ➔
Version 0.0 (2023-10-07 03:12:53.781000)

updates: Integration of the appointment of Professors Tony Mok and Steven Nathan to Alentis Therapeutics' Scientific Advisory Board

  • ➔
  • ➔